Airway remodelling in asthma

Current understanding and implications for future therapies

Mimi L. K. Tang, John W. Wilson, Alastair G. Stewart, Simon G. Royce

Research output: Contribution to journalArticleOtherpeer-review

73 Citations (Scopus)

Abstract

Airway remodelling refers to the structural changes that occur in the airway wall in asthma. These include epithelial hyperplasia and metaplasia, subepithelial fibrosis, muscle cell hyperplasia and angiogenesis. These structural changes result in thickening of the airway wall, airway hyperresponsiveness (AHR), and a progressive irreversible loss of lung function. The precise sequence of events that take place during the remodelling process and the mechanisms regulating these changes remain poorly understood. It is thought that airway remodelling is initiated and promoted by repeated episodes of allergic inflammation that damage the surface epithelium of the airway. However, other mechanisms are also likely to contribute to this process. Moreover, the interrelationship between airway remodelling, inflammation and AHR has not been clearly defined. Currently, there are no effective treatments that halt or reverse the changes of airway remodelling and its effects on lung function. Glucocorticoids have been unable to eliminate the progression of remodelling changes and there is limited evidence of a beneficial effect from other available therapies. The search for novel therapies that can directly target individual components of the remodelling process should be made a priority. In this review, we describe the current understanding of the airway remodelling process and the mechanisms regulating its development. The impact of currently available asthma therapies on airway remodelling is also discussed.
Original languageEnglish
Pages (from-to)474 - 488
Number of pages15
JournalPharmacology and Therapeutics
Volume112
Issue number2
DOIs
Publication statusPublished - Nov 2006
Externally publishedYes

Keywords

  • Airway remodelling
  • Asthma
  • Fibrosis
  • Therapy
  • Airway wall thickening
  • Allergic inflammation

Cite this

@article{1ab997ca55ef435bb627803566aa0f31,
title = "Airway remodelling in asthma: Current understanding and implications for future therapies",
abstract = "Airway remodelling refers to the structural changes that occur in the airway wall in asthma. These include epithelial hyperplasia and metaplasia, subepithelial fibrosis, muscle cell hyperplasia and angiogenesis. These structural changes result in thickening of the airway wall, airway hyperresponsiveness (AHR), and a progressive irreversible loss of lung function. The precise sequence of events that take place during the remodelling process and the mechanisms regulating these changes remain poorly understood. It is thought that airway remodelling is initiated and promoted by repeated episodes of allergic inflammation that damage the surface epithelium of the airway. However, other mechanisms are also likely to contribute to this process. Moreover, the interrelationship between airway remodelling, inflammation and AHR has not been clearly defined. Currently, there are no effective treatments that halt or reverse the changes of airway remodelling and its effects on lung function. Glucocorticoids have been unable to eliminate the progression of remodelling changes and there is limited evidence of a beneficial effect from other available therapies. The search for novel therapies that can directly target individual components of the remodelling process should be made a priority. In this review, we describe the current understanding of the airway remodelling process and the mechanisms regulating its development. The impact of currently available asthma therapies on airway remodelling is also discussed.",
keywords = "Airway remodelling, Asthma, Fibrosis, Therapy, Airway wall thickening, Allergic inflammation",
author = "Tang, {Mimi L. K.} and Wilson, {John W.} and Stewart, {Alastair G.} and Royce, {Simon G.}",
year = "2006",
month = "11",
doi = "10.1016/j.pharmthera.2006.05.001",
language = "English",
volume = "112",
pages = "474 -- 488",
journal = "Pharmacology and Therapeutics",
issn = "0163-7258",
publisher = "Elsevier",
number = "2",

}

Airway remodelling in asthma : Current understanding and implications for future therapies. / Tang, Mimi L. K.; Wilson, John W.; Stewart, Alastair G.; Royce, Simon G.

In: Pharmacology and Therapeutics, Vol. 112, No. 2, 11.2006, p. 474 - 488.

Research output: Contribution to journalArticleOtherpeer-review

TY - JOUR

T1 - Airway remodelling in asthma

T2 - Current understanding and implications for future therapies

AU - Tang, Mimi L. K.

AU - Wilson, John W.

AU - Stewart, Alastair G.

AU - Royce, Simon G.

PY - 2006/11

Y1 - 2006/11

N2 - Airway remodelling refers to the structural changes that occur in the airway wall in asthma. These include epithelial hyperplasia and metaplasia, subepithelial fibrosis, muscle cell hyperplasia and angiogenesis. These structural changes result in thickening of the airway wall, airway hyperresponsiveness (AHR), and a progressive irreversible loss of lung function. The precise sequence of events that take place during the remodelling process and the mechanisms regulating these changes remain poorly understood. It is thought that airway remodelling is initiated and promoted by repeated episodes of allergic inflammation that damage the surface epithelium of the airway. However, other mechanisms are also likely to contribute to this process. Moreover, the interrelationship between airway remodelling, inflammation and AHR has not been clearly defined. Currently, there are no effective treatments that halt or reverse the changes of airway remodelling and its effects on lung function. Glucocorticoids have been unable to eliminate the progression of remodelling changes and there is limited evidence of a beneficial effect from other available therapies. The search for novel therapies that can directly target individual components of the remodelling process should be made a priority. In this review, we describe the current understanding of the airway remodelling process and the mechanisms regulating its development. The impact of currently available asthma therapies on airway remodelling is also discussed.

AB - Airway remodelling refers to the structural changes that occur in the airway wall in asthma. These include epithelial hyperplasia and metaplasia, subepithelial fibrosis, muscle cell hyperplasia and angiogenesis. These structural changes result in thickening of the airway wall, airway hyperresponsiveness (AHR), and a progressive irreversible loss of lung function. The precise sequence of events that take place during the remodelling process and the mechanisms regulating these changes remain poorly understood. It is thought that airway remodelling is initiated and promoted by repeated episodes of allergic inflammation that damage the surface epithelium of the airway. However, other mechanisms are also likely to contribute to this process. Moreover, the interrelationship between airway remodelling, inflammation and AHR has not been clearly defined. Currently, there are no effective treatments that halt or reverse the changes of airway remodelling and its effects on lung function. Glucocorticoids have been unable to eliminate the progression of remodelling changes and there is limited evidence of a beneficial effect from other available therapies. The search for novel therapies that can directly target individual components of the remodelling process should be made a priority. In this review, we describe the current understanding of the airway remodelling process and the mechanisms regulating its development. The impact of currently available asthma therapies on airway remodelling is also discussed.

KW - Airway remodelling

KW - Asthma

KW - Fibrosis

KW - Therapy

KW - Airway wall thickening

KW - Allergic inflammation

UR - https://www.ncbi.nlm.nih.gov/pubmed/16759709

U2 - 10.1016/j.pharmthera.2006.05.001

DO - 10.1016/j.pharmthera.2006.05.001

M3 - Article

VL - 112

SP - 474

EP - 488

JO - Pharmacology and Therapeutics

JF - Pharmacology and Therapeutics

SN - 0163-7258

IS - 2

ER -